Healthtech Startups

Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.

1 investor

Alpyne Labs builds Aria, a practice automation platform that runs insurance eligibility checks, claim scrubbing, and reporting in the background for mental health group practices. It targets group practice owners looking to grow without proportionally increasing administrative and billing overhead.

1 investor

Alsteni Medical develops an intraoral gastrointestinal access device designed to deliver nutrient therapy for metabolic management. The company is advancing the device through FDA 510(k) clearance with clinical evidence and manufacturing partnerships in place.

1 investor

Altach Biomedical develops cartilage repair solutions for the orthopedic medical device industry. The company showcases its innovative technologies at major MedTech conferences to engage with investors and strategic partners.

1 investor

Altamash General Hospital is a 260-bed multi-specialty hospital offering medical and surgical departments, diagnostic imaging (X-ray, CT, MRI, ultrasound, endoscopy), a clinical laboratory, 24-hour emergency care, ICU/NICU, and pharmacy services. Located in Clifton, Karachi, it serves patients across Pakistan and grew out of Dr. Altamash's dental care practice.

1 investor

Alta Partners is a venture capital firm focused on life sciences and healthcare investments, with a portfolio that has generated over 90 FDA-approved products and includes both therapeutic companies and tech-enabled patient care services.

1 investor

AlterDiag is a diagnostics company founded by executives with backgrounds in immunology R&D and business strategy. The page focuses on the founding team and does not detail the specific product beyond its work in the diagnostics market.

1 investor

Alter Echo develops technology that keeps personnel outside cleanrooms while reducing disposable gown waste in pharmaceutical manufacturing. The company targets pharmaceutical facilities seeking to improve workplace safety, environmental sustainability, and operational efficiency.

1 investor

AlterG develops anti-gravity treadmill systems using patented Differential Air Pressure technology to enable rehabilitation and athletic training. The systems serve orthopedic rehabilitation, neurological condition management, active aging, and athletic performance improvement.

1 investor

ABio-X is a life sciences incubation platform that creates and invests in biotech and pharmaceutical companies developing innovative medicines and technologies. The platform provides capital, operational support, and access to experienced entrepreneurs and industry networks to accelerate drug development pipelines.

1 investor

Alteron Therapeutics is a pharmaceutical company focused on drug innovation. The available page does not detail its specific therapeutic areas or products.

1 investor

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma. The drug aims to stop viral infections before they trigger acute respiratory exacerbations, addressing the underlying viral cause rather than downstream inflammation.

1 investor

Althexis offers a subscription-based sales assistant tool that combines skin analysis with product recommendations, along with sponsored product placements and a business analytics platform providing anonymized demographic and behavioral data. It targets pharmacists and healthcare partners in the skincare retail space.

1 investor

Altilia provides an enterprise AI platform that enables businesses to create, customize, and deploy AI agents without specialized technical skills. The platform combines generative AI capabilities with an intuitive interface designed for organizations across industries to automate workflows and enhance decision-making.

1 investor

Alto Pax provides a confidentiality-first group therapy platform that connects patients with specialized mental health clinicians, addressing the shortage of care access through measurement-based group care models rather than traditional 1:1 therapy.

1 investor

Altratech develops point-of-care diagnostic technology for quantitative HIV viral load testing in low- and middle-income countries. The company creates affordable and accessible medical devices for resource-limited healthcare settings.

1 investor

Altro provides a platform for wellness businesses to offer clinical services like GLP-1 therapy, hormone therapy, peptides, and lab testing under their own brand, handling compliance, clinical oversight, and pharmacy operations. The service targets independent wellness practitioners including health coaches, medspas, fitness studios, and chiropractors seeking to expand their service offerings and revenue.

1 investor

Altruix operates local, independent pharmacies in the mid-Atlantic region, offering person-centered pharmacy services that specialize in behavioral health, intellectual and developmental disabilities, and substance use disorder. It focuses on helping people access and adhere to their prescribed treatments.

1 investor

Altus designs and manufactures mobile workstations, wall mounts, IoT-enabled carts, and OEM-integrated healthcare equipment for clinical and IT teams. The company produces all solutions in Michigan with locally sourced components.

1 investor

Altus provides fire alarm systems, sprinkler services, fire suppression equipment, fire extinguishers, and life safety solutions for building safety and emergency response.

1 investor

Alume Biosciences develops nerve illumination technology for surgery, including bevonescein (ALM-488), an injectable peptide that makes nerves glow to help surgeons identify and preserve them during procedures such as head-and-neck and prostate surgery. The drug candidate is in Phase 3 clinical trials, with a planned FDA New Drug Application submission in 2026.

1 investor

Alva Health develops wearable medical devices that continuously monitor for early signs of stroke and alert emergency responders in real time. The company serves patients at risk of stroke and the healthcare system, focusing on improving outcomes through rapid detection and treatment initiation.

1 investor

AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.

1 investor

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.

1 investor